智雲健康(09955.HK)成為錦波生物特定產品線下藥店獨家總經銷商
智雲健康(09955.HK)公布,與山西錦波生物訂立不具法律約束力的戰略合作協議,集團將成為錦波生物特定產品線下藥店渠道銷售的獨家總經銷商。
在合作期間,訂約方將利用集團線下藥店網絡就錦波生物健康產品的營銷推廣和產品銷售開展合作,集團還將利用其技術專長為錦波生物提供定制化軟件服務。訂約方希望通過業務合作以數字化的方式為錦波生物開拓更廣闊的市場並提升推廣效率,同時也為集團覆蓋的藥店提供優質的健康產品。
錦波生物主要從事以重組人源化膠原蛋白產品和抗HPV生物蛋白產品為核心產品的各類醫療器械、功能性護膚品的研發、生產及銷售,是全球首個重組人源化膠原蛋白生物新材料生產企業,並制定重組人源化膠原蛋白標準(YY/T1888-2023《重組人源化膠原蛋白》)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.